Saniona will host the research and development (R&D) day on
May 12, 2021
The virtual event will take place on Thursday, May 20, 2021, at 11:00 a.m. EDT / 5:00 p.m. CEST
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, announced today this he will host a virtual R&D day on Thursday, May 20, 2021 at 11:00 a.m. EDT / 5:00 p.m. CEST.
The main focus of the event will be on the company’s ion channel drug discovery engine and its startup pipeline. Presenters will include members of the Saniona research team and senior management, as well as Heike Wulff, Ph.D., professor of pharmacology at the Davis School of Medicine at the University of California (UC). The presentations will cover the following topics:
- The untapped potential of ion channels
- Saniona Ion Channel Drug Discovery Engine
- SAN903 (preclinical) for the treatment of rare inflammatory / fibrotic diseases
- SAN711 (Preclinical and Planned Phase 1) for the treatment of rare neuropathic disorders
Dr Wulff and the Saniona management team will be available to answer questions after the formal presentations.
To register for the R&D Day event, please click here.
Heike Wulff, Ph.D., obtained his Masters in Pharmaceutical Sciences and approval as an Apothecary in 1994 from the Pharmaceutical Institute at Christian Albrecht University in Kiel, Germany. In 1998, she obtained her doctorate. in Medicinal Chemistry in Kiel. Following her doctorate, she became a postdoctoral researcher in the laboratory of Dr. K. George Chandy in the Department of Physiology and Biophysics at the University of California at Irvine. In 2003, after training in molecular biology, electrophysiology and immunology, Dr Wulff obtained an assistant professor position at the University of California (UC), Davis. She was tenured in 2008 and is now Professor of Pharmacology at UC Davis, where she is an official instructor for the School of Medicine Pharmacology course and teaches basic pharmacology, pharmacokinetics, drug development and medicinal chemistry to medical students, undergraduate chemistry students, and graduate students. Dr. Wulff’s research focuses on the pharmacology of potassium channels and the design of novel ion channel modulator drugs and novel tool compounds. She is the author of 175 peer-reviewed publications on Blood Pressure and Ca2+-activated K+ channels and was ranked in the top 1% of most cited researchers in their field in the Clarivate 2020 review.
For more information please contact
Trista Morrison, Director of Communications, Saniona. Office: +1 (781) 810-9227. E-mail: [email protected]
This information has been submitted for publication, through the aforementioned contact persons, to 14.00 It’s certain May 12, 2021.
Saniona is a biopharmaceutical company focused on the discovery, development and delivery of innovative treatments for patients with rare diseases around the world. The company’s lead product candidate, Tesomet, is in interim clinical trials for hypothalamic obesity and Prader-Willi syndrome, serious rare conditions characterized by uncontrollable hunger and insoluble weight gain. Saniona’s robust drug discovery engine has generated a library of over 20,000 proprietary ion channel modulators, a largely untapped and scientifically validated class of drugs. Principal candidate SAN711 enters phase 1 for rare neuropathic disorders, while SAN903 for rare inflammatory and fibrotic disorders progresses during preclinical development. Led by an experienced scientific and operational team, Saniona has a research organization based in Copenhagen, Denmark and is building its headquarters in the Boston, Massachusetts, United States area. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Learn more at www.saniona.com.
RD Day Preview PR 12.05.21